Kura Oncology(KURA) - 2025 Q4 - Annual Results

Financial Performance - KOMZIFTI™ (ziftomenib) generated $2.1 million in net product revenue during the initial five-week commercial availability period ending December 31, 2025[5]. - Kura Oncology received milestone payments of $195 million under a collaboration agreement with Kyowa Kirin in Q4 2025[5]. - The company reported estimated collaboration revenue (non-cash item) for Q4 2025 between $15 million and $17 million[5]. - As of December 31, 2025, Kura had $667.3 million in cash, cash equivalents, and short-term investments[5]. - Kura's financial results for Q4 2025 are subject to completion of financial closing procedures, and actual results may differ materially from preliminary metrics[31]. Product Development and Approval - KOMZIFTI was granted full FDA approval on November 13, 2025, for adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible NPM1 mutation[7]. - KOMZIFTI™ (ziftomenib) is an FDA-approved oral menin inhibitor for adults with relapsed or refractory NPM1-mutated acute myeloid leukemia[29]. - The company anticipates non-cash collaboration revenue recognition of $45 million to $55 million in 2026[9]. - Kura plans to accelerate U.S. uptake of KOMZIFTI in R/R NPM1-m AML and drive quarter-over-quarter growth in net product revenue[9]. - The company aims to present updated data from the KOMET-007 trial in the first half of 2026[9]. - Kura is expanding ziftomenib to non-AML indications and advancing enrollment in various clinical trials throughout 2026[9]. - The company is excited about delivering meaningful impact for patients throughout 2026 and beyond, supported by a deep pipeline of transformative therapies[4]. - Kura Oncology is focused on precision medicines for cancer treatment, with a pipeline targeting hematologic malignancies and solid tumors[29]. - The company is advancing research in menin inhibition and farnesyl transferase inhibition[29]. Risks and Challenges - Forward-looking statements indicate potential risks affecting Kura's future operations and financial results, including market competition and regulatory approval[32]. - Kura anticipates cash runway and collaboration revenue recognition in 2026, but faces risks related to financing and product development[32]. - The company emphasizes the importance of monitoring for unexpected adverse side effects of its product candidates[32]. - Kura's collaboration with Kyowa Kirin is highlighted as a potential risk factor for future success[32]. - The company is committed to developing safe and effective therapeutics, navigating the complexities of drug commercialization[32]. Investor Relations - Investors and media inquiries can be directed to Greg Mann at Kura Oncology[33].